

"Express Mail" mailing label number <u>EL832893828US</u>	
Date of Deposit <u>09 MARCH 2005</u>	
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Printed Name <u>QUEEN THOMAS</u>	Signature <u>Queen Thomas</u>

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

First Applicant: HEUER Josef Georg

Serial No.: PCT/US2003/025855

Filed: September 10, 2003

For: METHOD FOR REDUCING MORBIDITY  
AND MORTALITY IN CRITICALLY ILL  
PATIENTS

Docket No.: X15747

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provide(s) a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

-2-

Respectfully submitted,



Lynn D. Apelgren  
Attorney/Agent for Applicant(s)  
Registration No. 45,341  
Phone: 317-276-6501

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

---

FORM PTO 1449 (modified)  INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X15747	Serial No. <b>10/527275</b> PCT/US2003/025855
	First Applicant HEUER Josef Georg	
	Filing Date September 10, 2003 PCT Nat'l Entry (if applicable)	Group

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	US 2002/0042367	04-11-2002	Stewart, T.	
	AB	US 2004/0126852	07-01-2004	Stewart, T.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	BA	WO 01/18210	03-15-2001	Genentech, Inc.		
	BB	WO 2004/026228	04-01-2004	Eli Lilly and Company		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T <sup>6</sup>
	CA	NEUMANN, B., <i>et al.</i> Mechanisms of acute inflammatory lung injury induced by sepsis. International Immunology, February 1999. Vol. 11, No. 2, pages 217-227.	
	CB	XIE, M-H., <i>et al.</i> FHF-19, A Novel Fibroblast Growth Factor With Unique Specificity For FHFR4. Cytokine. October 1999. Vol. 11, No. 10, pages 729-735.	
	CC	TOMLINSON, E., <i>et al.</i> Transgenic Mice Expressing Human Fibroblast Growth Factor-19 Display Increased Metabolic Rate and Decreased Adiposity. Endocrinology. May 2002. Vol. 143, No. 5, pages 1741-1747.	
	CD	RIEDEMANN, N., <i>et al.</i> The enigma of sepsis. The Journal of Clinical Investigation. August 2003. Vol. 112, No. 4, pages 460-467.	
Examiner Signature		Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of

document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.